<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282034</url>
  </required_header>
  <id_info>
    <org_study_id>ORT-12</org_study_id>
    <nct_id>NCT01282034</nct_id>
  </id_info>
  <brief_title>Study for the Treatment of Knee Chondral and Osteochondral Lesions</brief_title>
  <official_title>Multicenter Randomized Controlled Trial for the Treatment of Knee Chondral and Osteochondral Lesions: Marrow Stimulation Techniques vs MaioRegen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fin-Ceramica Faenza Spa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fin-Ceramica Faenza Spa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION Marrow stimulation techniques as subchondral drilling or microfractures&#xD;
      represent ones of the most frequently used methods for chondral and osteochodral defects&#xD;
      repair and considered as standard techniques.&#xD;
&#xD;
      MaioRegen® (Fin-Ceramica Faenza S.p.A., Italy) is a bioceramic, multi-layered scaffold, in a&#xD;
      single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium&#xD;
      enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is&#xD;
      able to promote the tissue regeneration in case of severe and large chondral/osteochondral&#xD;
      lesions, otherwise difficult to treat, as previously demonstrated in vitro, in vivo and in a&#xD;
      clinical study.&#xD;
&#xD;
      OBJECTIVES The present study proposes to compare MaioRegen® performances with respect to&#xD;
      reference standard surgical techniques (microfractures and subchondral drilling) for the&#xD;
      treatment of chondral/osteochondral lesions, in order to consolidate MaioRegen®, as&#xD;
      innovative surgical approach.&#xD;
&#xD;
      STUDY DESIGN The clinical trial is multicenter, prospective, randomized, controlled, two-arm,&#xD;
      single-blind and involves eleven European centres and 150 patients. Eligible subjects will be&#xD;
      randomly allocated to one of the two treatment groups: control group, treated with marrow&#xD;
      stimulation techniques, and treatment group, treated with MaioRegen® implant.&#xD;
&#xD;
      Patient defect will be evaluated pre-operatively and each patient enrolled must meet all the&#xD;
      entry criteria for the trial. Before enrolment, each subject should declare his voluntary&#xD;
      participation to the study by informed consent signature.&#xD;
&#xD;
      Arthroscopic control will be carried out immediately before the randomization and thus&#xD;
      surgical treatment, to confirm the characteristics of the lesion to be treated and finalizing&#xD;
      the recruitment.&#xD;
&#xD;
      For each patient 6, 12 and 24 months post-operative follow-up visits will be carried out and&#xD;
      during each follow-up visit the Case Report Form (CRF) will be filled in the specific&#xD;
      section.&#xD;
&#xD;
      Within the CRF, at each follow-up section, commonly used and specific scores will be assigned&#xD;
      for the established end-points (IKDC, KOOS, Tegner Score, VAS, MRI Mocart Scoring System).&#xD;
&#xD;
      Patients selected will be randomized to undergo one of two study groups, as prescribed by the&#xD;
      randomization list.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-operative MRI exams will be carried out for each patient during the follow-up visit, at&#xD;
      6, 12 and 24 months post-op., and centrally blind evaluated by two senior radiologists.&#xD;
&#xD;
      STATISTICS The study has been designed to demonstrate the superiority of MaioRegen® compared&#xD;
      to marrow stimulation techniques.&#xD;
&#xD;
      On the basis of previous evidence and, assuming a minimum difference in the modification of&#xD;
      the IKDC Subjective Knee Evaluation Score between MaioRegen® and the control therapy, the&#xD;
      sample size was estimated in 74 patients for group (power=90%, first type error α=5%,&#xD;
      drop-outs=10%), for a total sample size of 148 subjects.&#xD;
&#xD;
      The analysis of the primary end-point will be the evaluation of change from baseline to two&#xD;
      years, in IKDC Subjective Knee Evaluation Score, comparing the results between the two&#xD;
      groups.&#xD;
&#xD;
      Secondary end-points (functional improvement, quality of life improvement, tissue&#xD;
      regeneration) will undergo the same analyses as the primary end-point, for each follow-up&#xD;
      visit.&#xD;
&#xD;
      Frequency tables will be provided for overall judgement of the treatment. The incidence and&#xD;
      gravity frequency of eventual events after surgery will be tabulated.&#xD;
&#xD;
      The study will be conducted after approval by the ethics committee board of each centre and&#xD;
      possibly by the national competent authorities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IKDC Subjective Knee Evaluation Form-2000</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IKDC Knee Examination Form-2000</measure>
    <time_frame>six months and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS</measure>
    <time_frame>six months, one year, two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tegner score</measure>
    <time_frame>six months, one year, two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Visual Analogue Scale) for pain evaluation</measure>
    <time_frame>six months, one year, two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI exam and MOCART score</measure>
    <time_frame>six months, one year, two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Knee Chondral Lesion</condition>
  <condition>Knee Osteochondral Lesion</condition>
  <arm_group>
    <arm_group_label>Marrow stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical device: MaioRegen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Marrow stimulation - Drilling or Microfractures</intervention_name>
    <description>Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.&#xD;
Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective.</description>
    <arm_group_label>Marrow stimulation</arm_group_label>
    <other_name>subchondral Drilling</other_name>
    <other_name>Steadman's Microfractures</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MaioRegen Surgery</intervention_name>
    <description>MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.</description>
    <arm_group_label>Medical device: MaioRegen</arm_group_label>
    <other_name>osteochondral scaffold</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients provided written informed consent;&#xD;
&#xD;
          2. Patients aged between 18 and 60 years;&#xD;
&#xD;
          3. Knee symptomatic chondral lesion of grade III/IV (according to Outerbridge&#xD;
             Classification) or osteochondral lesion;&#xD;
&#xD;
          4. Not re-fixable OCD lesions;&#xD;
&#xD;
          5. Lesion between 2-9 cm2;&#xD;
&#xD;
          6. Single lesion;&#xD;
&#xD;
          7. Patients agreed to actively participate in the rehabilitation protocol and follow-up&#xD;
             program;&#xD;
&#xD;
          8. Male or female patients;&#xD;
&#xD;
          9. Women of childbearing age had to use a proven method to prevent pregnancy, before the&#xD;
             surgical treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients incapable to understanding and will;&#xD;
&#xD;
          2. Patients participating in previous, concurrent or not, trials (ongoing or completed&#xD;
             within 3 months);&#xD;
&#xD;
          3. Patients surgically treated for the same defect within one year;&#xD;
&#xD;
          4. Known allergy to collagen or calcium-phosphates;&#xD;
&#xD;
          5. Patients affected by malignancy;&#xD;
&#xD;
          6. Patients affected by metabolic or thyroid disorders;&#xD;
&#xD;
          7. Patients used to alcohol or drug (medication) abuse;&#xD;
&#xD;
          8. Patients affected by advanced osteoarthritis (Kellgren-Lawrence grade ≥3);&#xD;
&#xD;
          9. Patients affected by synovitis;&#xD;
&#xD;
         10. Untreated patellofemoral malalignment;&#xD;
&#xD;
         11. Varus or valgus malalignment exceeding 5°;&#xD;
&#xD;
         12. Body Mass Index &gt; 30;&#xD;
&#xD;
         13. Patients previously treated for total or partial meniscectomy (&gt;50% of the meniscus&#xD;
             dimension);&#xD;
&#xD;
         14. Multiple lesions;&#xD;
&#xD;
         15. Kissing lesions;&#xD;
&#xD;
         16. Chondral/osteochondral tibial plate defects;&#xD;
&#xD;
         17. Concomitant menisci and chondral/osteochondral defects to be treated;&#xD;
&#xD;
         18. Untreated knee ligament instability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurilio Marcacci, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituti Ortopedici Rizzoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH University Hospital</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gent Univeristy Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>79098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedal Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ortopedici Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital HF</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District hospital of orthopaedics</name>
      <address>
        <city>Piekary Slaskie</city>
        <state>Katowice</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sport Science Orthopaedic Clinic</name>
      <address>
        <city>CapeTown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kungsbacka Hospital</name>
      <address>
        <city>Kungsbacka</city>
        <zip>43440</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schulthess Klinik</name>
      <address>
        <city>Zurich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>January 21, 2011</study_first_submitted>
  <study_first_submitted_qc>January 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHONDRAL</keyword>
  <keyword>OSTEOCHONDRAL</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

